Printer Friendly

VICAL LICENCEE ANGES MG FILES NDA IN JAPAN FOR COLLATEGENE.

Vical Incorporated (NASDAQ:VICL), San Diego, Calif., has announced the company's licensee, AnGes MG, Inc., reported submission on of a New Drug Application (NDA) to the Japanese Ministry of Health, Labor and Welfare for its angiogenesis product candidate, Collategene, for treatment of critical limb ischemia. The treatment uses Vical technology to deliver a gene encoding hepatocyte growth factor (HGF), a human protein that causes growth of blood vessels in areas of restricted blood flow.

"The Japanese NDA filing positions Collategene to be the first product based on our DNA delivery technology with the potential to be approved for human use," said Vijay B. Samant, president and Chief Executive Officer of Vical. "In the United States, where it is estimated that more than 10 million people have peripheral arterial disease (PAD), AnGes already has completed two Phase 2 clinical trials of Collategene in PAD patients. This product candidate offers a novel approach to addressing an important, unserved medical need in the Japanese market, and has the potential to expand into the much larger markets worldwide. This NDA filing by AnGes is an important milestone in advancing nonviral gene therapy toward regulatory and commercial acceptance."

The NDA submission follows positive results announced in June 2007 following interim analysis of data from the first 41 subjects to complete a Phase 3 trial of Collategene. Based on the findings that the primary efficacy endpoint in the trial had been achieved with statistical significance and that there were no major safety concerns related to treatment, an Independent Data Monitoring Committee recommended stopping the trial early to prevent potential ethical issues against the placebo group subjects.

In the trial, 40 subjects with critical limb ischemia (advanced peripheral arterial disease) were evaluated for efficacy. The primary endpoints, improvement of rest pain (Visual Analog Scale, or VAS) or ischemic ulcer size, at 12 weeks post dosing, showed 30.8% improvement in the placebo group and 70.4% improvement in the treatment group, a statistically significant difference (p=0.014).

The following English translation of the original Japanese news release was provided by AnGes.

AnGes Submits NDA for HGF Gene Therapy

AnGes MG, Inc.(TSE Mothers:4563, http://www.anges-mg.com) has submitted its New Drug Application (NDA) to MHLW (Japan) for HGF Gene Therapy (INN : beperminogene perplasmid, Brand Name : Collategene) to treat Critical Limb Ischemia (CLI) in Arteriosclerosis Obliterans (ASO) and Burger's disease, on March 27, 2008.

HGF Gene Therapy is a product, where a gene which induces HGF protein is injected to the ischemic lesion, leading to the formation of new blood vessels through the effect of the HGF protein, which results in improvement of the ischemic symptoms.

AnGes has developed this product for peripheral arterial diseases (ASO and Burger's Disease), which occurs by decreased blood flow caused by narrowing of blood vessels as a result of arteriosclerosis, and ischemic heart disease.

This is a product with a novel mechanism of action different from existing products, so that it may also be effective to patients in which existing therapeutics were not effective, or, surgical treatments can not be pursued. As for safety, we are using naked DNA delivery method instead of viral vectors to transfect genes, so that there won't be any safety concerns often caused by viral vectors in case of gene therapies.

HGF is a gene therapy product originally developed in Japan through the research at Academia, and development went ahead in Japan first.

Since last June, when we got the positive results at the interim analysis of our Phase III study in Japan for ASO patients with CLI, we have prepared for submission, and are pleased to be the first company in Japan to submit an NDA for a gene therapy product.

AnGes is aiming to provide this product to patients also worldwide. After approval, the brand name in Japan will be "Collategene". The name comes from the meaning of formation of "collateral vessels" by angiogenesis and improvement of ischemic symptoms by "gene therapy."

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs.

For more information, visit http://www.vical.com or call 858/646-1127 and visit http://www.anges-mg.com.
COPYRIGHT 2008 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Worldwide Biotech
Date:May 1, 2008
Words:807
Previous Article:PAREXEL EXPANDS RELATIONSHIP WITH SYNCHRON IN INDIA.
Next Article:BIOTAGE LAUNCHES NEW 24 WELL PYROSEQUENCING SYSTEM.
Topics:


Related Articles
AnGes MG to Start Phase I Clinical Trial of NF-kappa B Decoy Oligodeoxynucleotide for Atopic Dermatitis.
AnGes MG, Seikagaku to Dissolve Joint Development Agreement for NFkB Decoy-Oligo-based Intraarticular Injection.
AnGes MG Announces Results of Phase I Clinical Trial of HGF Gene Medicine.
AnGes MG, Vical to Collaborate in Developing Genomic Drug for Skin Cancer.
AnGes MG Unveils Future Development Strategies for HGF Gene Medicine.
AnGes MG, Vical to Start Phase III Clinical Trial of Allovectin for Gene Therapy.
AnGes MG, Inc. Submits BLA for Naglazyme in Japan.
AnGes MG, Inc. Launches Naglazyme in Japan.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters